[1]
|
Travis, W.D., Brambilla, E., Nicholson, A.G., et al. (2015) The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. Journal of Thoracic Oncology, 10, 1243-1260. https://doi.org/10.1097/JTO.0000000000000630
|
[2]
|
张童童, 李峻岭. 存在驱动基因突变肺鳞癌患者的临床病理特征及预后分析[J]. 中国肺癌杂志, 2016, 19(10): 648-652.
|
[3]
|
Soyano, A.E., Dholaria, B., Marin-Acevedo, J.A., et al. (2018) Peripheral Blood Biomarkers Correlate with Outcomes in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1 Antibodies. The Journal for ImmunoTherapy of Cancer, 6, 129. https://doi.org/10.1186/s40425-018-0447-2
|
[4]
|
唐高燕, 刘琰, 张青云, 等. NLR和PLR动态变化预测PD-1/PD-L1治疗晚期非小细胞肺癌患者疗效及预后的价值[J]. 现代肿瘤医学, 2023, 31(12): 2247-2254.
|
[5]
|
Khan, S., Jain, M., Mathur, V., et al. (2016) Chronic Inflammation and Cancer: Paradigm on Tumor Progression, Metastasis and Therapeutic Intervention. Gulf Journal of Oncology, 1, 86-93.
|
[6]
|
Grivennikov, S.I., Greten, F.R. and Karin, M. (2010) Immunity, Inflammation, and Cancer. Cell, 140, 883-899. https://doi.org/10.1016/j.cell.2010.01.025
|
[7]
|
Bryant, A.K., Sankar, K., Strohbehn, G.W., et al. (2022) Prognostic and Predictive Value of Neutrophil-to-Lymphocyte Ratio with Adjuvant Immunotherapy in Stage III Non-Small-Cell Lung Cancer. Lung Cancer, 163, 35-41. https://doi.org/10.1016/j.lungcan.2021.11.021
|
[8]
|
Ksienski, D., Wai, E.S., Alex, D., et al. (2021) Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Tumor Expression Receiving Pembrolizumab. Translational Lung Cancer Research, 10, 355-367. https://doi.org/10.21037/tlcr-20-541
|
[9]
|
Kutlu, Y., Aydin, S.G., Bilici, A., et al. (2023) Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers in Patients with Extensive-Stage Small Cell Lung Cancer Treated with Atezolizumab in Combination with Chemotherapy. Medicine (Baltimore), 102, e33432. https://doi.org/10.1097/MD.0000000000033432
|
[10]
|
Bayraktaroglu, M. and Yildiz, B.P. (2023) Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer. Medicine (Baltimore), 102, e34180. https://doi.org/10.1097/MD.0000000000034180
|
[11]
|
Platini, H., Ferdinand, E., Kohar, K., et al. (2022) Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis. Medicina (Kaunas), 58, Article No. 1069. https://doi.org/10.3390/medicina58081069
|
[12]
|
Pirlog, C.F., Cotan, H.T., Parosanu, A., et al. (2022) Correlation between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer. Cureus, 14, e26843. https://doi.org/10.7759/cureus.26843
|
[13]
|
Tang, Y., Cui, Y., Li, L.L., et al. (2021) Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer. Cancer Management and Research, 13, 8241-8255. https://doi.org/10.2147/CMAR.S329963
|
[14]
|
Nakaya, A., Kurata, T., Yoshioka, H., et al. (2018) Neutrophil-to-Lymphocyte Ratio as an Early Marker of Outcomes in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. International Journal of Clinical Oncology, 23, 634-640. https://doi.org/10.1007/s10147-018-1250-2
|
[15]
|
Xiong, Q., Huang, Z., Xin, L., et al. (2021) Post-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Response to Anti-PD-1/PD-L1 Antibody in SCLC Patients at Early Phase. Cancer Immunology, Immunotherapy, 70, 713-720. https://doi.org/10.1007/s00262-020-02706-5
|
[16]
|
Li, Y., Zhang, Z., Hu, Y., et al. (2020) Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Immune Checkpoint Inhibitors (ICIs). Frontiers in Oncology, 10, Article No. 654. https://doi.org/10.3389/fonc.2020.00654
|
[17]
|
Fujimoto, A., Toyokawa, G., Koutake, Y., et al. (2021) Association between Pretreatment Neutrophil-to-Lymphocyte Ratio and Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer. Thoracic Cancer, 12, 2198-2204. https://doi.org/10.1111/1759-7714.14063
|
[18]
|
Pavan, A., Calvetti, L., Dal, Maso, A., et al. (2019) Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Oncologist, 24, 1128-1136. https://doi.org/10.1634/theoncologist.2018-0563
|
[19]
|
Schlesinger, M. (2018) Role of Platelets and Platelet Receptors in Cancer Metastasis. Journal of Hematology & Oncology, 11, Article No. 125. https://doi.org/10.1186/s13045-018-0669-2
|
[20]
|
Cho, U., Park, H.S., Im, S.Y., et al. (2018) Prognostic Value of Systemic Inflammatory Markers and Development of a Nomogram in Breast Cancer. PLOS ONE, 13, E0200936. https://doi.org/10.1371/journal.pone.0200936
|
[21]
|
Jiang, Y., Xu, D., Song, H., et al. (2021) Inflammation and Nutrition-Based Biomarkers in the Prognosis of Oesophageal Cancer: A Systematic Review and Meta-Analysis. BMJ Open, 11, E048324. https://doi.org/10.1136/bmjopen-2020-048324
|
[22]
|
Russo, A., Russano, M., Franchina, T., et al. (2020) Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. Advances in Therapy, 37, 1145-1155. https://doi.org/10.1007/s12325-020-01229-w
|
[23]
|
Ding, N., Pang, Z., Shen, H., et al. (2016) The Prognostic Value of PLR in Lung Cancer: A Meta-Analysis Based on Results from a Large Consecutive Cohort. Scientific Reports, 6, Article No. 34823. https://doi.org/10.1038/srep34823
|
[24]
|
Huai, Q., Luo, C., Song, P., et al. (2023) Peripheral Blood Inflammatory Biomarkers Dynamics Reflect Treatment Response and Predict Prognosis in Non-Small Cell Lung Cancer Patients with Neoadjuvant Immunotherapy. Cancer Science, 114, 4484-4498. https://doi.org/10.1111/cas.15964
|
[25]
|
Chen, Y., Wen, S., Xia, J., et al. (2021) Association of Dynamic Changes in Peripheral Blood Indexes with Response to PD-1 Inhibitor-Based Combination Therapy and Survival among Patients with Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 12, Article ID: 672271. https://doi.org/10.3389/fimmu.2021.672271
|
[26]
|
Olgun, P. and Diker, O. (2023) Sixth-Week Immune-Nutritional-Inflammatory Biomarkers: Can They Predict Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors? Current Oncology, 30, 10539-10549. https://doi.org/10.3390/curroncol30120769
|
[27]
|
Liu, J., Li, S., Zhang, S., et al. (2019) Systemic Immune-Inflammation Index, Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio Can Predict Clinical Outcomes in Patients with Metastatic Non-Small-Cell Lung Cancer Treated with Nivolumab. Journal of Clinical Laboratory Analysis, 33, E22964. https://doi.org/10.1002/jcla.22964
|
[28]
|
MacDonald, M., Poei, D., Leyba, A., et al. (2023) Real World Prognostic Utility of Platelet Lymphocyte Ratio and Nutritional Status in First-Line Immunotherapy Response in Stage IV Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications, 36, Article ID: 100752. https://doi.org/10.1016/j.ctarc.2023.100752
|
[29]
|
Liu, W., Liu, Y., Ma, F., et al. (2021) Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors. Cancer Management and Research, 13, 765-771. https://doi.org/10.2147/CMAR.S293200
|
[30]
|
Weide, B., Martens, A., Hassel, J.C., et al. (2016) Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 22, 5487-5496. https://doi.org/10.1158/1078-0432.CCR-16-0127
|
[31]
|
Wan, L., Wu, C., Luo, S., et al. (2022) Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors. Disease Markers, 2022, Article ID: 3610038. https://doi.org/10.1155/2022/3610038
|
[32]
|
Lang, C., Egger, F., Alireza Hoda, M., et al. (2022) Lymphocyte-to-Monocyte Ratio Is an Independent Prognostic Factor in Surgically Treated Small Cell Lung Cancer: An International Multicenter Analysis. Lung Cancer, 169, 40-46. https://doi.org/10.1016/j.lungcan.2022.05.010
|
[33]
|
Liu, Z., Diao, Y. and Li, X. (2022) Body Mass Index and Serum Markers Associated with Progression-Free Survival in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. BMC Cancer, 22, Article No. 824. https://doi.org/10.1186/s12885-022-09744-5
|
[34]
|
Jin, J., Yang, L., Liu, D., et al. (2021) Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Lung Cancer: A Systematic Review and Meta-Analysis. Technology in Cancer Research & Treatment, 20. https://doi.org/10.1177/1533033820983085
|
[35]
|
Song, Y.-J., Wang, L.-X., Hong, Y.-Q., et al. (2015) Lymphocyte to Monocyte Ratio Is Associated with Response to First-Line Platinum-Based Chemotherapy and Prognosis of Early-Stage Non-Small Cell Lung Cancer Patients. Tumor Biology, 37, 5285-5293. https://doi.org/10.1007/s13277-015-4397-8
|
[36]
|
Egami, S., Kawazoe, H., Hashimoto, H., et al. (2021) Peripheral Blood Biomarkers Predict Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Treated with Pembrolizumab: A Multicenter Retrospective Study. Journal of Cancer, 12, 2105-2112. https://doi.org/10.7150/jca.53242
|
[37]
|
Chan, S.W.S., Smith, E., Aggarwal, R., et al. (2021) Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-Analysis. Clinical Lung Cancer, 22, 390-407. https://doi.org/10.1016/j.cllc.2021.01.002
|
[38]
|
Rossi, S., Toschi, L., Finocchiaro, G., et al. (2020) Neutrophil and Lymphocyte Blood Count as Potential Predictive Indicators of Nivolumab Efficacy in Metastatic Non-Small-Cell Lung Cancer. Immunotherapy, 12, 715-724. https://doi.org/10.2217/imt-2019-0154
|
[39]
|
Sekine, K., Kanda, S., Goto, Y., et al. (2018) Change in the Lymphocyte-to-Monocyte Ratio Is an Early Surrogate Marker of the Efficacy of Nivolumab Monotherapy in Advanced Non-Small-Cell Lung Cancer. Lung Cancer, 124, 179-188. https://doi.org/10.1016/j.lungcan.2018.08.012
|
[40]
|
Li, B., Wang, S., Li, C., et al. (2019) The Kinetic Changes of Systemic Inflammatory Factors During Bevacizumab Treatment and Its Prognostic Role in Advanced Non-Small Cell Lung Cancer Patients. Journal of Cancer, 10, 5082-5089. https://doi.org/10.7150/jca.30478
|
[41]
|
Li, A., Mu, X., He, K., et al. (2020) Prognostic Value of Lymphocyte-to-Monocyte Ratio and Systemic Immune-Inflammation Index in Non-Small-Cell Lung Cancer Patients with Brain Metastases. Future Oncology, 16, 2433-2444. https://doi.org/10.2217/fon-2020-0423
|
[42]
|
Yan, H., Cai, L., Chen, S., et al. (2020) Preoperative Lymphocyte-to-Monocyte Ratio versus Platelet-to-Lymphocyte Ratio as a Prognostic Predictor for Non-Small Cell Lung Cancer Patients. Journal of Medical Biochemistry, 39, 160-164.
|
[43]
|
Gao, J., Zhang, P., Tang, M., et al. (2023) Predictors of Immune Checkpoint Inhibitor-Related Adverse Events in Older Patients with Lung Cancer: A Prospective Real-World Analysis. Journal of Cancer Research and Clinical Oncology, 149, 8993-9006. https://doi.org/10.1007/s00432-023-04792-1
|
[44]
|
Zhu, L, R., Li, J., Chen, P., et al. (2016) Clinical Significance of Plasma Fibrinogen and D-Dimer in Predicting the Chemotherapy Efficacy and Prognosis for Small Cell Lung Cancer Patients. Clinical and Translational Oncology, 18, 178-188. https://doi.org/10.1007/s12094-015-1350-7
|
[45]
|
Çalışkan, S. and Sungur, M. (2017) Fibrinogen and D-Dimer Levels in Prostate Cancer: Preliminary Results. Prostate International, 5, 110-112. https://doi.org/10.1016/j.prnil.2017.05.001
|
[46]
|
Dai, H., Zhou, H., Sun, Y., et al. (2018) D-Dimer as a Potential Clinical Marker for Predicting Metastasis and Progression in Cancer. Biomedical Reports, 9, 453-457. https://doi.org/10.3892/br.2018.1151
|
[47]
|
Yi, J., Chen, H., Li, J., et al. (2022) The Association between ROS1 Rearrangement and Risk of Thromboembolic Events in Patients with Advanced Non-Small Cell Lung Cancer: A Multicenter Study in China. Thrombosis Journal, 20, Article No. 56. https://doi.org/10.1186/s12959-022-00417-8
|
[48]
|
Liu, Q., He, J., Ning, R., et al. (2020) Pretreatment Plasma D-Dimer Levels as an Independent Prognostic Factor for Overall Survival among Patients with Advanced Non-Small-Cell Lung Cancer. Journal of International Medical Research, 48. https://doi.org/10.1177/0300060520962661
|
[49]
|
Li, X., Lu, D., Zhang, Z., et al. (2022) Prognostic Value of Plasma D-Dimer Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Retrospective Study. Journal of Thoracic Disease, 14, 4125-4135. https://doi.org/10.21037/jtd-22-1363
|
[50]
|
Chen, C., Li, J., Li, J., et al. (2020) Application of an Elevated Plasma D-Dimer Cut-Off Value Improves Prognosis Prediction of Advanced Non-Small Cell Lung Cancer. Annals of Translational Medicine, 8, 1153. https://doi.org/10.21037/atm-20-5947
|
[51]
|
Chen, Y., Yu, H., Wu, C., et al. (2016) Prognostic Value of Plasma D-Dimer Levels in Patients with Small-Cell Lung Cancer. Biomedicine & Pharmacotherapy, 81, 210-217. https://doi.org/10.1016/j.biopha.2016.02.030
|
[52]
|
Zaborowska-Szmit, M., Kowalski, D.M., Piórek, A., et al. (2016) A Decrease in D-Dimer Concentration and an Occurrence of Skin Rash as Iatrogenic Events and Complementary Predictors of Survival in Lung Cancer Patients Treated with EGFR Tyrosine Kinase Inhibitors. Pharmacological Reports, 68, 1140-1148. https://doi.org/10.1016/j.pharep.2016.07.003
|